Cited by 64Long-Term Effects of COVID-19SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

The neurobiology of SARS-CoV-2 infection

Meinhardt, Jenny, Streit, Simon, Dittmayer, Carsten, Manitius, Regina v., Radbruch, Helena, Heppner, Frank L.·2024·Nature Reviews Neuroscience

Abstract

Worldwide, over 694 million people have been infected with SARS-CoV-2, with an estimated 55-60% of those infected developing COVID-19. Since the beginning of the pandemic in December 2019, different variants of concern have appeared and continue to occur. With the emergence of different variants, an increasing rate of vaccination and previous infections, the acute neurological symptomatology of COVID-19 changed. Moreover, 10-45% of individuals with a history of SARS-CoV-2 infection experience symptoms even 3 months after disease onset, a condition that has been defined as 'post-COVID-19' by the World Health Organization and that occurs independently of the virus variant. The pathomechanisms of COVID-19-related neurological complaints have become clearer during the past 3 years. To date, there is no overt - that is, truly convincing - evidence for SARS-CoV-2 particles in the brain. In this Review, we put special emphasis on discussing the methodological difficulties of viral detection in CNS tissue and discuss immune-based (systemic and central) effects contributing to COVID-19-related CNS affection. We sequentially review the reported changes to CNS cells in COVID-19, starting with the blood-brain barrier and blood-cerebrospinal fluid barrier - as systemic factors from the periphery appear to primarily influence barriers and conduits - before we describe changes in brain parenchymal cells, including microglia, astrocytes, neurons and oligodendrocytes as well as cerebral lymphocytes. These findings are critical to understanding CNS affection in acute COVID-19 and post-COVID-19 in order to translate these findings into treatment options, which are still very limited.

Integrity signals

Registry

Crossref · 10.1038/s41583-023-00769-8

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • COVID-19 is very rarely neuroinvasive, but its impact on the brain might be immune-mediated and cause glial neuroinflammation.

    “Indeed, while COVID-19 is very rarely neuroinvasive [127], its impact on the brain might be immune-mediated [126] and cause glial neuroinflammation [128,129,130].”

    From Revisiting the Pathogenesis of X-Linked Adrenoleukodystrophy (2025) · cites this paper as [127]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Meinhardt, J., Streit, S., Dittmayer, C., Manitius, R. V., Radbruch, H., & Heppner, F. L.
Affiliations
  • Humboldt-Universität zu Berlin (DE)
  • German Center for Neurodegenerative Diseases (DE)
Corresponding author
Heppner, Frank L.
Venue
Nature Reviews Neuroscience
Published
2023-12-04
Volume
25
Issue
1
Pages
30-42
ISSN
  • 1471-003X (ISSN-L)
  • 1471-0048
OpenAlex
W4389298735
Cited by
64
References
12
Citations by year
2026: 15 · 2025: 26 · 2024: 23
FWCI
2.60
Type
journal article
Language
en
Open access
closed
Locations
  • Nature reviews. Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
  • DZNE Pub (submittedVersion)
Topics
  • Health Sciences › Medicine › Neurology › Long-Term Effects of COVID-19
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
SARS-CoV-2, COVID-19 pandemic, long COVID, neurological complications, blood-brain barrier, blood-CSF barrier, microglia, astrocytes, neurons, oligodendrocytes, immune response, SARS-CoV-2 variants
MeSH terms
COVID-19, SARS-CoV-2, Blood-Brain Barrier, Brain, Central Nervous System, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review